^
Association details:
| Biomarker: | FGFR fusion |
|---|---|
| Cancer: | Childhood B Acute Lymphoblastic Leukemia |
| Drug: | dasatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Pediatric Acute Lymphoblastic Leukemia: Regimen components…Induction…vincristine, dexamethasone or prednisone, daunorubicin, pegaspargase; IT therapy: cytarabine then methotrexate…Consolidation…For CRLF2- and ABL class kinase fusion: cyclophosphamide, cytarabine, 6-MP, vincristine, pegaspargase + dasatinib; IT therapy: methotrexate
Secondary therapy:
cytarabine + cyclophosphamide + methotrexate + vincristine + pegaspargase + DR6MP
